Open AccessDevelopment of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine
Author(s) -
Andrew Cox,
Steven F. Baker,
Aitor Nogales,
Luis MartínezSobrido,
Stephen Dewhurst
Publication year - 2015
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.02636-14
Subject(s) - live attenuated influenza vaccine , virology , attenuated vaccine , in vivo , biology , virus , lethality , influenza a virus , influenza vaccine , orthomyxoviridae , immunology , virulence , genetics , gene
The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safetyin vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom